Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Upcoming SlideShare
DUB
Next

32

Share

Abnormal uterine bleeding and Management

public-ally.....

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Abnormal uterine bleeding and Management

  1. 2. Disorders of the Menstrual Cycle <ul><li>Amenorrhea </li></ul><ul><li>Dysmenorrhea </li></ul><ul><li>Premenstrual Syndrome </li></ul><ul><li>Abnormal Uterine Bleeding </li></ul>
  2. 3. Abnormal Uterine Bleeding: Definitions <ul><li>Menorrhagia : Heavy or prolonged uterine bleeding that occurs at regular intervals. Some sources define further as the loss of ≥ 80 mL blood per cycle or bleeding > 7 days. </li></ul><ul><li>Hypomenorrhea: Periods with unusually light flow, often associated with hypogonadotropic hypogonadism (athletes, anorexia). Also may be associated with Asherman’s syndrome </li></ul><ul><li>Metrorrhagia: Irregular menstrual bleeding or bleeding between periods </li></ul><ul><li>Menometrorrhagia: Metrorrhagia associated with > 80 mL </li></ul><ul><li>Polymenorrhea: Frequent menstrual bleeding. Strictly, menses occur q 21 d or less </li></ul><ul><li>Oligomenorrhea: Menses are > 35 d apart. Most commonly caused by PCOS, pregnancy, and anovulation </li></ul>
  3. 4. Abnormal Uterine Bleeding: Differential Diagnosis <ul><li>Structural </li></ul><ul><ul><li>Cervical or vaginal laceration </li></ul></ul><ul><ul><li>Uterine or cervical polyp </li></ul></ul><ul><ul><li>Uterine leiomyoma </li></ul></ul><ul><ul><li>Adenomyosis </li></ul></ul><ul><ul><li>Cervical stenosis/Asherman’s (hypomenorrhea) </li></ul></ul><ul><li>Hormonal </li></ul><ul><ul><li>Anovulatory bleeding </li></ul></ul><ul><ul><li>Hypogonadotropic hypogonadism </li></ul></ul><ul><ul><li>Pregnancy </li></ul></ul><ul><ul><li>Hormonal Contraception (i.e. OCPs, Depo-Provera) </li></ul></ul><ul><ul><li>Thyroid disorders </li></ul></ul><ul><ul><li>Hyperprolactinemia </li></ul></ul><ul><li>Malignancy </li></ul><ul><ul><li>Uterine or Cervical cancer </li></ul></ul><ul><ul><li>Endometrial hyperplasia (potentially pre-malignant) </li></ul></ul><ul><li>Bleeding disorders </li></ul><ul><ul><li>von Willebrand’s Disease, Hemophilia/Factor deficiencies, platelet disorders </li></ul></ul>
  4. 5. Abnormal Uterine Bleeding: Workup <ul><li>History </li></ul><ul><ul><li>Timing of bleeding, quantity of bleeding, menstrual hx including menarche and recent periods, associated sxs, family hx of bleeding disorders </li></ul></ul><ul><li>Physical </li></ul><ul><ul><li>R/o vaginal or cervical source of bleeding. Bimanual may reveal bulky uterus/discrete fibroids </li></ul></ul><ul><ul><li>Assess for obesity, hirsutism, stigmata of thyroid disease, signs of hyperprolactinemia (visual field testing, galactorrhea) </li></ul></ul><ul><ul><li>Pap smear </li></ul></ul><ul><ul><li>Endometrial biopsy, if appropriate </li></ul></ul><ul><li>Pregnancy Test </li></ul><ul><li>Imaging </li></ul><ul><ul><li>Pelvic ultrasound </li></ul></ul><ul><ul><li>Sonohystogram or hysterosalpingogram </li></ul></ul><ul><li>Surgical </li></ul><ul><ul><li>Hysteroscopy </li></ul></ul><ul><ul><li>D & C </li></ul></ul>
  5. 6. Normal Menstrual Cycle
  6. 7. Normal Ovulatory Cycle <ul><li>Follicular development  ovulation (d14)  corpus luteal function  luteolysis </li></ul><ul><li>Endometrium is exposed to: </li></ul><ul><ul><li>Ovarian production of estrogen  </li></ul></ul><ul><ul><li>(proliferation) </li></ul></ul><ul><ul><li>Combination of estrogen and progesterone  </li></ul></ul><ul><ul><li>(secretory phase) </li></ul></ul><ul><ul><li>Estrogen and progesterone withdrawal </li></ul></ul><ul><ul><ul><li>(desquamation and repair) </li></ul></ul></ul>
  7. 8. Anovulatory Bleeding <ul><li>Corpus luteum is not produced </li></ul><ul><ul><li>Ovary fails to secrete progesterone, although estrogen production continues </li></ul></ul><ul><ul><li>Result is continuous, unopposed E stimulation of endometrium: </li></ul></ul><ul><ul><ul><li>Endometrial proliferation without P-induced differentiation / stabilization </li></ul></ul></ul><ul><ul><li>Endometrium becomes excessively vascular without stromal support  fragility and irregular endometrial bleeding </li></ul></ul>
  8. 9. Anovulatory Bleeding: Etiologies <ul><li>Hyperandrogenic anovulation (PCOS, CAH, androgen-producing tumors) </li></ul><ul><li>Hypothalamic dysfunction (stress, anorexia, exercise) </li></ul><ul><li>Hyperprolactinemia </li></ul><ul><li>Hypothyroidism </li></ul><ul><li>Primary pituitary disease </li></ul><ul><li>Premature ovarian failure </li></ul><ul><li>Iatrogenic (secondary to radiation or chemo) </li></ul>
  9. 10. Anovulatory Bleeding: Adolescents (13-18 years) <ul><li>Anovulatory bleeding may be normal physiologic process, with ovulatory cycles not established until 1-2 yrs after menarche (immature HPG axis) </li></ul><ul><li>Screen for coagulation disorders (PT/PTT, plts) </li></ul><ul><li>May be caused by leukemia, ITP, hypersplenism </li></ul><ul><li>Consider endometrial bx in adolescents with 2-3 year history of untreated anovulatory bleeding, especially if obese </li></ul>
  10. 11. Anovulatory Bleeding: Management in Adolescents <ul><li>High dose estrogen therapy for acute bleeding episodes (promotes rapid endometrial growth to cover denuded endometrial surfaces): conjugated equine estrogens PO up to 10 mg/d in 4 divided doses or IV 25 mg q 4 hrs for 24 hrs </li></ul><ul><li>Treat pts with blood dyscrasias for their specific diseases, r/o leukemia </li></ul><ul><li>Prevent recurrent anovulatory bleeding with: </li></ul><ul><ul><ul><li>cyclic progestin (i.e. Provera) </li></ul></ul></ul><ul><ul><ul><li> or </li></ul></ul></ul><ul><ul><ul><li>low dose (≤ 35 μg ethinyl estradiol) oral contraceptive </li></ul></ul></ul><ul><ul><ul><ul><li>suppresses ovarian and adrenal androgen production and increases SHBG  decreasing bioavailable androgens </li></ul></ul></ul></ul>
  11. 12. Anovulatory Bleeding: Reproductive Age (19-39 years) <ul><li>Anovulatory bleeding not considered physiologic, evaluation required </li></ul><ul><li>6-10% of women have hyperandrogenic chronic anovulation (i.e. PCOS), characterized by noncyclic bleeding, hirsutism, obesity (BMI ≥ 25) </li></ul><ul><ul><li>Underlying biochemical abnormalities: noncyclic estrogen production, elevated serum testosterone, hypersecretion of LH, hyperinsulinemia. </li></ul></ul><ul><ul><li>h/o rapidly progressing hirsutism with virilization  suggests tumor </li></ul></ul><ul><li>Lab testing: HCG, TSH, fasting serum prolactin </li></ul><ul><ul><li>If androgen-producing tumor is suspected, serum DHEAS and testosterone levels </li></ul></ul><ul><ul><li>If POF suspected, serum FSH </li></ul></ul><ul><li>Chronic anovulation resulting from hypothalamic dysfunction (dx’d by low FSH level) may be due to excessive psychologic stress, exercise, or weight loss </li></ul>
  12. 13. Anovulatory Bleeding: Reproductive Age (19-39 yrs) <ul><li>When is endometrial evaluation indicated? </li></ul><ul><li>Sharp increase in incidence of endometrial CA from 2.3/100,000 ages 30-34 yrs  6.1/100,000 ages 35-39 yrs </li></ul><ul><li>Therefore, endometrial bx to exclude CA is indicated in any woman > 35 yrs old with suspected anovulatory bleeding </li></ul><ul><li>Pts 19-35 who don’t respond to medical therapy or have prolonged periods of unopposed estrogen 2/2 anovulation merit endometrial bx </li></ul>
  13. 14. Anovulatory Bleeding: Reproductive Age (19-39 yrs) <ul><li> Medical therapies </li></ul><ul><li>Can be treated safely with either cyclic progestin or OCPs, similar to adolescents. </li></ul><ul><li>Estrogen-containing OCPs </li></ul><ul><ul><li>relatively contraindicated in women with HTN or DM </li></ul></ul><ul><ul><li>contraindicated for women > 35 who smoke or have h/o thromboembolic dz </li></ul></ul><ul><li>If pregnancy is desired, ovulation induction with clomid is initial tx of choice </li></ul><ul><ul><li>Can induce withdrawal bleed with progestin (i.e. provera), followed by initiation of therapy with Clomid, 50 mg/d for 5 days, starting b/t days 3 and 5 of menstrual cycle </li></ul></ul>
  14. 15. Anovulatory Bleeding: Later Reproductive Age (40-Menopause) <ul><li>Incidence of anovulatory bleeding increases toward end of reproductive years </li></ul><ul><li>In perimenopausal women, onset of anovulatory cycles is due to declining ovarian function. </li></ul><ul><li>Can initiate hormone therapy for cycle control </li></ul><ul><li>When is endometrial evaluation indicated? </li></ul><ul><li>Incidence of endometrial CA in women 40-49 years: 36.2/100,000 </li></ul><ul><li>All women > 40 yrs who present with suspected anovulatory bleeding merit endometrial bx after excluding pregnancy </li></ul>
  15. 16. Anovulatory Bleeding: Later Reproductive Age (40-Menopause) <ul><li> Medical therapy </li></ul><ul><li>Cyclic progestin, low-dose OCPs, or cyclic HRT are all options </li></ul><ul><li>Women with hot flashes secondary to decreased estrogen production can have symptomatic relief with ERT in combination with continuous or cyclic progestin </li></ul>
  16. 17. Anovulatory Bleeding: Later Reproductive Age (40-Menopause) <ul><li>Surgical therapy </li></ul><ul><li>Surgical options include: hysterectomy and endometrial ablation </li></ul><ul><li>Surgical tx only indicated when medical mgmt has failed and childbearing complete </li></ul><ul><li>Some studies suggest hysterectomy may have higher long-term satisfaction than ablation </li></ul><ul><li>Endometrial ablation: NovaSure, thermal balloon </li></ul><ul><ul><li>YAG laser and rollerball less widely-used currently </li></ul></ul><ul><ul><li>45% of women achieve amenorrhea after YAG laser or resectoscope. 12 month post-op satisfaction is 90%. Only 15% of women achieve amenorrhea after thermal balloon ablation, and 1 yr satisfaction rate still 90% </li></ul></ul><ul><ul><li>Long-term satisfaction with ablation may be lower: </li></ul></ul><ul><ul><ul><li>in 3-year f/u study, 8.5% of women who had undergone ablation were re-ablated, an additional 8.5% had hyst </li></ul></ul></ul><ul><ul><ul><li>In a 5-year follow up study, 34% of women who underwent ablation later had a hyst. </li></ul></ul></ul>
  • SaranyaChakaravarthi

    Jun. 28, 2021
  • HarshalKatore

    Sep. 24, 2020
  • AishwaryaSingh67

    Sep. 25, 2019
  • dhyeydhamelia7

    Jul. 15, 2018
  • DeepakGelot

    Jul. 4, 2018
  • muhammadajmal89

    Jan. 11, 2018
  • Sngta

    Aug. 22, 2017
  • HelenaNamibiaAfrica

    Jul. 24, 2017
  • KamalAmroota

    May. 17, 2017
  • piyuaashu

    Apr. 14, 2017
  • SaadAbuDayyeh

    Jun. 8, 2016
  • DjChangamireMarz

    May. 23, 2016
  • mmbmvc

    Feb. 25, 2016
  • mohamedelshereef245

    Dec. 28, 2015
  • JebelJemal

    Jul. 31, 2015
  • KaviArasan17

    Jul. 9, 2015
  • merog1

    May. 13, 2015
  • nhonnguyen568

    Mar. 30, 2015
  • nileprincess05

    Feb. 10, 2015
  • maygohery

    Jan. 12, 2015

public-ally.....

Views

Total views

7,649

On Slideshare

0

From embeds

0

Number of embeds

2

Actions

Downloads

0

Shares

0

Comments

0

Likes

32

×